BIOAF (Bioasis Technologies) Pretax Margin %: -660.36% (As of Nov. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BIOAF Bioasis Technologies Inc BIOAF
12 GF Score
Price $0.00
View Full Analysis

What is Bioasis Technologies Pretax Margin %?

Bioasis Technologies BIOAF 12 Pretax Margin % is -660.36% as of Nov. 2022. GuruFocus rates BIOAF with a GF Score™ of 12/100.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Bioasis Technologies's Pre-Tax Income for the three months ended in Nov. 2022 was $-0.73 Mil. Bioasis Technologies's Revenue for the three months ended in Nov. 2022 was $0.11 Mil. Therefore, Bioasis Technologies's pretax margin for the quarter that ended in Nov. 2022 was -660.36%.

The historical rank and industry rank for Bioasis Technologies's Pretax Margin % or its related term are showing as below:


BIOAF's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.42
* Ranked among companies with meaningful Pretax Margin % only.

Bioasis Technologies  (OTCPK:BIOAF) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Bioasis Technologies Pretax Margin % Related Terms

Bioasis Technologies Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Bioasis Technologies's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioasis Technologies Pretax Margin % Chart

Bioasis Technologies Annual Data
Trend Feb13 Feb14 Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -899.15 -244.10 -669.52 17.12 -7,763.33

Bioasis Technologies Quarterly Data
Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,373.33 0.00 0.00 -907.53 -660.36

BIOAF vs VRTX, REGN, SGEN: Pretax Margin % Comparison

For the Biotechnology subindustry, Bioasis Technologies's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioasis Technologies Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioasis Technologies's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Bioasis Technologies's Pretax Margin % falls into.


BIOAF
12GF Score
Bioasis Technologies Inc BIOAF
Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioasis Technologies Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Bioasis Technologies's Pretax Margin for the fiscal year that ended in Feb. 2022 is calculated as

Pretax Margin=Pre-Tax Income (A: Feb. 2022 )/Revenue (A: Feb. 2022 )
=-2.329/0.03
=-7,763.33 %

Bioasis Technologies's Pretax Margin for the quarter that ended in Nov. 2022 is calculated as

Pretax Margin=Pre-Tax Income (Q: Nov. 2022 )/Revenue (Q: Nov. 2022 )
=-0.733/0.111
=-660.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of -660.36% mean?
Bioasis Technologies (BIOAF) has a Pretax Margin % of -660.36% as of Nov. 2022. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Bioasis Technologies and its competitors.
Is Bioasis Technologies' Pretax Margin % too high?
Bioasis Technologies' current Pretax Margin % is -660.36%. Overall, Bioasis Technologies has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bioasis Technologies' Pretax Margin % compare to VRTX and REGN?
Bioasis Technologies' Pretax Margin % of -660.36% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Bioasis Technologies and its competitors. Bioasis Technologies's current Pretax Margin % is -660.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioasis Technologies stock overvalued right now?
Bioasis Technologies (BIOAF) has a current Pretax Margin % of -660.36%. The current Pretax Margin % is -660.36%. Bioasis Technologies' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Bioasis Technologies (BIOAF), the current Pretax Margin % is -660.36% as of Nov. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bioasis Technologies Business Description

Address 157 Church Street, 19th Floor, New Haven, CT, USA, 06510
Bioasis Technologies Inc is a development stage biopharmaceutical company engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company's xB3 program describes its proprietary carrier, p97, and components thereof, to deliver therapeutics across the blood-brain barrier (BBB).
12GF Score

Get the complete analysis for BIOAF

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price